Tirosint is an endocrinological drug owned by Institut Biochimique. It contains the active ingredient, levothyroxine sodium, and is available in capsule; oral dosage forms. Tirosint was first authorized for market use on 13th October 2006.
The generics of Tirosint are anticipated to be released after 14th March 2024 due to the expiry of the two drug patents held by Institut Biochimique. This includes the drug patents US7691411 and US7723390.
Tirosint is primarily used in the management of thyroid-related conditions. Thanks to its active ingredient - levothyroxine sodium, Tirosint effectively replaces or provides more thyroid hormone, which is normally produced by the thyroid gland.
Tirosint has two significant patents that are key to the release date of Tirosint generic. The patents, namely: US7691411 titled 'Pharmaceutical formulae for thyroid hormones and procedures for obtaining them' and US7723390 titled 'Pharmaceutical formulations for thyroid hormones' expire on the same date, 14th March 2024. Below are the details of the patent: